局部晚期乳腺癌新辅助化疗的5年疗效分析  

Analysis to five-year curative effect of neoadjuvant chemotherapy on local advanced breast cancer.

作　　者：付彬玉[1] 李卉[1] 陶苹[1] 谢旭林[1] 程娜[1] 

机构地区：[1]四川省肿瘤医院放化疗科乳腺科,四川成都610041

出　　处：《四川医学》2008年第7期836-837,共2页Sichuan Medical Journal

摘　　要：目的探讨局部晚期乳腺癌新辅助化疗后的远期临床疗效。方法回顾性分析了30例(A组)Ⅲa、Ⅲb期患者采用ECF方案新辅助化疗后的5年生存率(OS),无病生存率(DFS)及无病生存期。ECF方案具体为E-ADM70mg/m2第1天,CTX500mg/m2第1、8天,5-FU500mg/m2第18、天,每21d为1周期,术前化疗2周期,并与同期未行新辅助化疗的30例Ⅲa期患者(B组)进行比较。结果两组患者在5年OS、DFS及无病生存期方面比较,差异均无统计学意义(P>0.05);A组患者新辅助化疗的有效率为53.33%,80.0%的患者分期降低,16.67%的患者达到保乳手术要求。结论新辅助化疗可明显降低局部晚期乳腺癌患者的分期,显著地提高了对肿瘤局部的治疗效果;通过新辅助化疗可观察到肿瘤对化疗药物的敏感性;通过新辅助化疗后还可降低或延缓局部晚期乳腺癌患者的复发转移,提高了患者的生存质量,达到了最佳治疗效果。Objective To discuss the long-term effect of neoadjuvant chemotherapy on local advanced breast cancer.Methods Review and analyze the five-year overall survival rate,disease free survival rate and disease free survival time of 30 stage Ⅲa,Ⅲb breast cancer patients（A Group）accepted ECF neoadjuvant chemotherapy treatment with the detaile chemotherapy scheme as below：E-ADM 70mg/m^2（1^st day）,CTX 500mg/m^2（1^st day,8^th day） and 5-Fu 500mg/m^2（1^st day,8^th day）,every 21 days as a cycle,carried out 2 cycles before operation;And compared those with 30 Stage Ⅲa patients（B Group）without neoadjuvant chemotherapy treatment.Results The is no significant differnece on the five-year overall survival rate,disease free survival rate and disease free survival time between two groups patients（P〉0.05）.Among A Group patients,the effective rate of neoadjuvant chemotherapy was 53.33%,the pathological stages of 80% of patients declined,16.67% of patients can accept the keep-breast operration.Conclusion The neoadjuvant chemotherapy can reduce the stages of local advanced breast cancer patients and increase the curative effect on partial tumor obviously;Also can help to observe the sensitivity of chemical medicine;reduce or delay recurrence or metastasis,raise the life quality of patients for best curative effect.

关 键 词：局部晚期乳腺癌 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]